Patents by Inventor Christophe Baudouin

Christophe Baudouin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENE SIGNATURE FOR THE PROGNOSIS OF DRY EYE DISEASE
    Publication number: 20220098669
    Abstract: Disclosed is a signature including at least 3 markers, as well as a method for the prognosis of dry eye disease in a subject, wherein the method includes assessing the expression of markers of a signature in a sample from the subject. Also disclosed is a kit for implementing this method.
    Type: Application
    Filed: December 15, 2021
    Publication date: March 31, 2022
    Inventors: Christophe BAUDOUIN, Philippe DAULL, Karima KESSAL
  • GENE SIGNATURE FOR THE PROGNOSIS OF DRY EYE DISEASE
    Publication number: 20190093165
    Abstract: Disclosed is a signature including at least 3 markers, as well as a method for the prognosis of dry eye disease in a subject, wherein the method includes assessing the expression of markers of a signature in a sample from the subject. Also disclosed is a kit for implementing this method.
    Type: Application
    Filed: February 28, 2017
    Publication date: March 28, 2019
    Inventors: Christophe BAUDOUIN, Philippe DAULL, Karima KESSAL
  • Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
    Patent number: 9555045
    Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: January 31, 2017
    Assignee: SANTEN SAS
    Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
  • METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL
    Publication number: 20160346406
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 1, 2016
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventors: William ROSTENE, Christophe BAUDOUIN, David GODEFROY, Alexandre DENOYER
  • Method for increasing the intraocular pressure in an animal
    Patent number: 9439981
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: September 13, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventors: William Rostene, Christophe Baudouin, David Godefroy, Alexandre Denoyer
  • Pharmaceutical composition for use in the treatment of glaucoma
    Patent number: 9095591
    Abstract: The present invention relates to a compound which is an antagonist of CXCR3 or an inhibitor of the CXCR3 receptor expression for the treatment of glaucoma.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: August 4, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: William Rostene, Alexandre Denoyer, Christophe Baudouin, David Godefroy
  • Use of prostaglandins F2Alpha and analogues for the healing of corneal and conjunctival lesions
    Patent number: 9072750
    Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: July 7, 2015
    Assignee: SANTEN SAS
    Inventors: Jean-Sébastien Garrigue, Frédéric Lallemand, Philippe Daull, Christophe Baudouin
  • METHOD FOR INCREASING THE INTRAOCULAR PRESSURE IN AN ANIMAL
    Publication number: 20140178308
    Abstract: The present invention concerns a method for inducing an increase in the intraocular pressure in an animal, said method comprising ocular administration of a solution comprising benzalkonium chloride (BAK). The present invention further relates to an animal having ocular hypertension, said animal being obtained by the method according to the invention. Said animal provides a convenient animal model for better understanding of the patho-physiological mechanisms involved in ocular hypertension and glaucoma. The present invention also relates to the use of said animal for screening a compound for therapeutic use against ocular hypertension or glaucoma, and/or for assessing potential side-effects of treatment of ocular hypertension and glaucoma.
    Type: Application
    Filed: July 27, 2012
    Publication date: June 26, 2014
    Applicant: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: William Rostene, Christophe Baudouin, David Godefroy, Alexandre Denoyer
  • PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF GLAUCOMA
    Publication number: 20130172370
    Abstract: The present invention relates to a compound which is an antagonist of CXCR3 or an inhibitor of the CXCR3 receptor expression for the treatment of glaucoma.
    Type: Application
    Filed: June 24, 2011
    Publication date: July 4, 2013
    Applicant: VT IDIRECT ,INC.
    Inventors: William Rostene, Alexandre Denoyer, Christophe Baudouin, David Godefroy
  • Use of Prostaglandins F2Alpha and Analogues for the Healing of Corneal and Conjunctival Lesions
    Publication number: 20120225939
    Abstract: The invention relates to a composition for use in treating corneal and conjunctival lesions, wherein the composition comprises a prostaglandin F2alpha or analogue, in a therapeutic amount, said composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative; the invention also relates to a method for treating surface ocular conditions in a patient in need thereof, comprising administering a composition of the invention.
    Type: Application
    Filed: November 19, 2010
    Publication date: September 6, 2012
    Applicant: NOVAGALI PHARMA SA
    Inventors: Jean-Sebastien Garrigue, Frederic Lallemand, Philippe Daull, Christophe Baudouin
  • USE OF PROSTAGLANDINS F2ALPHA AND ANALOGUES FOR THE HEALING OF CORNEAL AND CONJUNCTIVAL LESIONS
    Publication number: 20110118349
    Abstract: A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.
    Type: Application
    Filed: November 19, 2010
    Publication date: May 19, 2011
    Applicant: NOVAGALI PHARMA S.A.
    Inventors: Jean-Sébastien GARRIGUE, Frédéric LALLEMAND, Philippe DAULL, Christophe BAUDOUIN
  • Use of antioxidant for treating and/or preventing surface ocular disorders
    Publication number: 20030228299
    Abstract: The invention relates to a pharmaceutical composition for the treatment of superficial eye disorders.
    Type: Application
    Filed: February 13, 2003
    Publication date: December 11, 2003
    Inventors: Marie-Therese Droy-Lefaix, Christophe Baudouin